Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome-Reference-Cited by-同舟云学术

Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Published:2024-04-26 Issue:5 Volume:11 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Muehlberg Leonora¹,Pabst Thomas²,Largiadèr Carlo³,Aebi Yolanda³,Hayoz Michael³,Muehlethaler Konrad⁴,Zimmerli Stefan¹,Hirzel Cédric¹^ORCID

Affiliation:

1. Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland

2. Department of Medical Oncology, Inselspital, Bern University Hospital , Bern , Switzerland

3. Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern , Bern , Switzerland

4. Department of Clinical Microbiology, Institute for Infectious Diseases, University of Bern , Bern , Switzerland

Abstract

Abstract Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofae263/57409165/ofae263.pdf

Reference22 articles.

1. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia;Cornely;N Engl J Med,2007

2. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease;Ullmann;N Engl J Med,2007

3. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation;Sanchez-Ortega;Bone Marrow Transplant,2011

4. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients–a retrospective analysis of a single medical center in Taiwan;Wang;J Microbiol Immunol Infect,2016

5. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma;Jang;Clin Pharmacol Ther,2010